

Company Number: 57086

Coghlan's Chemist Ltd
Abridged Unaudited Financial Statements
for the financial year ended 31 March 2025

Coghlan's Chemist Ltd
CONTENTS

	Page
Director and Other Information	3
Director's Responsibilities Statement	4
Statement of Financial Position	5
Statement of Changes in Equity	6
Notes to the Financial Statements	7 - 10

Coghlan's Chemist Ltd
DIRECTOR AND OTHER INFORMATION

Director	Brid Coghlan
Company Secretary	Denis Coghlan
Company Number	57086
Registered Office	Coghlan's Chemist Limited 98/99 Main Street Carrick on Suir Tipperary Ireland
Business Address	Coghlan's Chemist Limited 98/99 Main Street Carrick on Suir Tipperary Tipperary Ireland
Accountants	Comerford Foley Chartered Accountants Unit 502 Riverstown 5 Complex Riverstown Business Park Tramore Waterford
Bankers	Allied Irish Banks Plc 41 Main Street Carrick-on-Suir Co. Tipperary
Solicitors	Derivan Sexton New Street Carrick-on-Suir Co. Tipperary

Coghlan's Chemist Ltd

DIRECTOR'S RESPONSIBILITIES STATEMENT

for the financial year ended 31 March 2025

The director is responsible for preparing the Director's Report and the financial statements in accordance with applicable Irish law and regulations.

Irish company law requires the director to prepare financial statements for each financial year. Under that law, the director has elected to prepare the financial statements in accordance with the Companies Act 2014 and FRS 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland", applying Section 1A of that Standard, issued by the Financial Reporting Council. Under company law, the director must not approve the financial statements unless they is satisfied that they give a true and fair view of the assets, liabilities and financial position of the company as at the financial year end date and of the profit or loss of the company for the financial year and otherwise comply with the Companies Act 2014.

In preparing these financial statements, the director is required to:

- select suitable accounting policies for the company financial statements and then apply them consistently;
- make judgements and accounting estimates that are reasonable and prudent;
- state whether the financial statements have been prepared in accordance with applicable accounting standards, identify those standards, and note the effect and the reasons for any material departure from those standards; and
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the company will continue in business.

The director is responsible for ensuring that the company keeps or causes to be kept adequate accounting records which correctly explain and record the transactions of the company, enable at any time the assets, liabilities, financial position and profit or loss of the company to be determined with reasonable accuracy, enable them to ensure that the financial statements and Director's Report comply with the Companies Act 2014. They is also responsible for safeguarding the assets of the company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

Signed on behalf of the board

Brid Coghlan
Director

21 October 2025

Coghlan's Chemist Ltd
STATEMENT OF FINANCIAL POSITION

as at 31 March 2025

	Notes	2025 €	2024 €
Non-Current Assets			
Financial assets	6	<u>7,336,046</u>	<u>7,938,540</u>
Current Assets			
Debtors	7	49,336	-
Cash and cash equivalents		<u>10,733</u>	<u>59,424</u>
		<u>60,069</u>	<u>59,424</u>
Creditors: amounts falling due within one year	8	-	(904,568)
Net Current Assets/(Liabilities)		<u>60,069</u>	<u>(845,144)</u>
Total Assets less Current Liabilities		<u>7,396,115</u>	<u>7,093,396</u>
Provisions for liabilities	9	<u>(246,525)</u>	<u>(208,533)</u>
Net Assets		<u><u>7,149,590</u></u>	<u><u>6,884,863</u></u>
Capital and Reserves			
Called up share capital presented as equity		5,000	5,000
Other reserves	10	1,250	1,250
Retained earnings		<u>7,143,340</u>	<u>6,878,613</u>
Equity attributable to owners of the company		<u><u>7,149,590</u></u>	<u><u>6,884,863</u></u>

The financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies' regime and in accordance with FRS 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland", applying Section 1A of that Standard.

I as Director of Coghlan's Chemist Ltd, state that -

(a) the company is availing itself of the exemption provided for by Chapter 15 of Part 6 of the Companies Act 2014,

(b) the company is availing itself of the exemption on the grounds that the conditions specified in section 358 are satisfied,

(c) the shareholders of the company have not served a notice on the company under section 334(1) in accordance with section 334(2),

(d) I acknowledge the company's obligations under the Companies Act 2014, to keep adequate accounting records and prepare financial statements which give a true and fair view of the assets, liabilities and financial position of the company at the end of its financial year and of its profit or loss for such a financial year and to otherwise comply with the provisions of the Companies Act 2014 relating to financial statements so far as they are applicable to the company,

(e) the company has relied on the specified exemption contained in section 352 Companies Act 2014. The company has done so on the grounds that the company is entitled to the benefit of that exemption as a small company and the abridged financial statements have been properly prepared in accordance with section 353 Companies Act 2014 and the small companies' regime.

Approved by the board on 21 October 2025 and signed on its behalf by:

Brid Coghlan
Director

Coghlan's Chemist Ltd
STATEMENT OF CHANGES IN EQUITY

as at 31 March 2025

	Called up share capital €	Retained earnings €	Capital redemption reserve €	Total €
At 1 April 2023	5,000	6,195,550	1,250	6,201,800
Profit for the financial year	-	683,063	-	683,063
At 31 March 2024	5,000	6,878,613	1,250	6,884,863
Profit for the financial year	-	264,727	-	264,727
At 31 March 2025	5,000	7,143,340	1,250	7,149,590

Coghlan's Chemist Ltd

NOTES TO THE ABRIDGED FINANCIAL STATEMENTS

for the financial year ended 31 March 2025

1. General Information

Coghlan's Chemist Ltd is a company limited by shares incorporated in Ireland. Coghlan's Chemist Limited, 98/99 Main Street, Carrick on Suir, Tipperary, Ireland is the registered office, which is also the principal place of business of the company. The nature of the company's operations and its principal activities are set out in the Director's Report. The financial statements have been presented in Euro (€) which is also the functional currency of the company.

2. Summary of Significant Accounting Policies

The following accounting policies have been applied consistently in dealing with items which are considered material in relation to the company's financial statements.

Statement of compliance

The financial statements of the company for the year ended 31 March 2025 have been prepared in accordance with the provisions of FRS 102 Section 1A (Small Entities) and the Companies Act 2014.

Basis of preparation

The financial statements have been prepared on the going concern basis and in accordance with the historical cost convention except for certain properties and financial instruments that are measured at revalued amounts or fair values, as explained in the accounting policies below. Historical cost is generally based on the fair value of the consideration given in exchange for assets. The financial reporting framework that has been applied in their preparation is the Companies Act 2014 and FRS 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" Section 1A, issued by the Financial Reporting Council.

The company qualifies as a small company as defined by section 280A of the Companies Act 2014 in respect of the financial year, and has applied the rules of the 'Small Companies Regime' in accordance with section 280C of the Companies Act 2014 and Section 1A of FRS 102.

Judgements in applying accounting policies and key sources of estimation uncertainty

Preparation of the financial statements requires management to make significant judgements and estimates. The resulting accounting estimates will, by definition, seldom equal the related results.

However none of the estimates and assumptions have a significant risk of causing a material adjustment to the carrying amounts of the assets and liabilities in the next financial year.

Financial assets

Investments are initially measured at fairvalue which usually equates to the transaction price and subsequently at fair value where investments are listed on an active market or where non listed investments can be reliably measured. Movements in fair value are measured in the profit and loss.

When fair value cannot be measured reliably or can no longer be measured reliably, investments are measured at cost less impairment.

Trade and other debtors

Trade and other debtors are initially recognised at fair value and thereafter stated at amortised cost using the effective interest method less impairment losses for bad and doubtful debts except where the effect of discounting would be immaterial. In such cases the receivables are stated at cost less impairment losses for bad and doubtful debts.

Cash and cash equivalents

Cash and cash equivalents comprise cash at bank and in hand, demand deposits with banks and other short-term highly liquid investments with original maturities of three months or less and bank overdrafts. In the Statement of Financial Position bank overdrafts are shown within Creditors.

Provisions

Provisions are recognised when the company has a present legal or constructive obligation arising as a result of a past event, it is probable that an outflow of economic benefits will be required to settle the obligation and a reliable estimate can be made. Provisions are measured at the present value of the expenditures expected to be required to settle the obligation using a pre-tax rate that reflects current market assessments of the same value of money and the risks specific to the obligation. The increase in the provision due to passage of time is recognised as interest expense.

Coghlan's Chemist Ltd

NOTES TO THE ABRIDGED FINANCIAL STATEMENTS

for the financial year ended 31 March 2025

Trade and other creditors

Trade and other creditors are initially recognised at fair value and thereafter stated at amortised cost using the effective interest rate method, unless the effect of discounting would be immaterial, in which case they are stated at cost.

Taxation and deferred taxation

Current tax represents the amount expected to be paid or recovered in respect of taxable profits for the financial year and is calculated using the tax rates and laws that have been enacted or substantially enacted at the Statement of Financial Position date.

Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the balance sheet date where transactions or events have occurred at that date that will result in an obligation to pay more tax in the future, or a right to pay less tax in the future. Timing differences are temporary differences between the company's taxable profits and its results as stated in the financial statements.

Deferred tax is measured on an undiscounted basis at the tax rates that are anticipated to apply in the periods in which the timing differences are expected to reverse, based on tax rates and laws that have been enacted or substantively enacted by the balance sheet date.

Foreign currencies

Monetary assets and liabilities denominated in foreign currencies are translated at the rates of exchange ruling at the Statement of Financial Position date. Non-monetary items that are measured in terms of historical cost in a foreign currency are translated at the rates of exchange ruling at the date of the transaction. Non-monetary items that are measured at fair value in a foreign currency are translated using the exchange rates at the date when the fair value was determined. The resulting exchange differences are dealt with in the Income Statement.

Ordinary share capital

The ordinary share capital of the company is presented as equity.

3. Income from investments	2025	2024
	€	€
Investment income	<u>12</u>	<u>12</u>
4. Other Gains and Losses	2025	2024
	€	€
Fair value gains and losses are as follows:		
Investments in shares	<u>308,890</u>	<u>938,297</u>

Adjustment to the value of listed investments, to value at market value.

5. Employees

The average monthly number of employees, including director, during the financial year was 0.00|0, (2024 - 0).

Coghlan's Chemist Ltd
NOTES TO THE ABRIDGED FINANCIAL STATEMENTS
for the financial year ended 31 March 2025

6. Financial fixed assets

	Other unlisted investments €	Total €
Investments Cost or Valuation		
At 1 April 2024	7,996,937	7,996,937
Disposals	(874,044)	(874,044)
Revaluations	271,550	271,550
	<u>7,394,443</u>	<u>7,394,443</u>
At 31 March 2025	<u>7,394,443</u>	<u>7,394,443</u>
Provision for diminution in value:		
At 31 March 2025	<u>58,397</u>	<u>58,397</u>
Net book value		
At 31 March 2025	<u>7,336,046</u>	<u>7,336,046</u>
At 31 March 2024	<u>7,938,540</u>	<u>7,938,540</u>

7. Debtors

	2025 €	2024 €
Other debtors	<u>49,336</u>	<u>-</u>

**8. Creditors
Amounts falling due within one year**

	2025 €	2024 €
Amounts owed to related parties (Note 13)	-	4,568
Director's current account (Note 12)	-	900,000
	<u>-</u>	<u>904,568</u>

9. Provisions for liabilities

The amounts provided for deferred taxation are analysed below:

	Other differences €	Total 2025 €	Total 2024 €
At financial year start	208,533	208,533	-
Charged to profit and loss	37,992	37,992	208,533
	<u>246,525</u>	<u>246,525</u>	<u>208,533</u>
At financial year end	<u>246,525</u>	<u>246,525</u>	<u>208,533</u>

10. Income Statement

	Income statement €	Capital redemption reserve €	Total €
At 1 April 2024	6,878,613	1,250	6,879,863
Profit for the financial year	264,727	-	264,727
	<u>7,143,340</u>	<u>1,250</u>	<u>7,144,590</u>
At 31 March 2025	<u>7,143,340</u>	<u>1,250</u>	<u>7,144,590</u>

Coghlan's Chemist Ltd
NOTES TO THE ABRIDGED FINANCIAL STATEMENTS

for the financial year ended 31 March 2025

11. Capital commitments

The company had no material capital commitments at the year-ended 31st March 2024

12. Director's transactions

The following amounts are repayable to the director:

	2025	2024
	€	€
Brid Coghlan	-	900,000
	<u> </u>	<u> </u>

13. Related party transactions

Net balances with related parties:

	2025	2024
	€	€
Trading amounts owed to related parties	-	4,568
	<u> </u>	<u> </u>

14. Controlling interest

By virtue of her 100% shareholding in the company, Mrs Brid Coghlan is the ultimate controlling party.

15. Events After the End of the Reporting Period

There have been no significant events affecting the company since the financial year-end.

16. Approval of financial statements

The financial statements were approved and authorised for issue by the board on 21 October 2025.